Bendamustine and melphalan kill myeloma cells similarly through reactive oxygen species production and activation of the p53 pathway and do not overcome resistance to each other

Leukemia and Lymphoma

Volumn 55, Issue 9, 2014, Pages 2165-2173

  Surget, Sylvanie ^a,b,c   Lemieux Blanchard, Emilie ^a,b,c   Maïga, Sophie ^a,b,c   Descamps, Géraldine ^a,b,c   Le Gouill, Steven ^a,b,c,d   Moreau, Philippe ^b,d   Amiot, Martine ^a,b,c   Pellat Deceunynck, Catherine ^a,b,c,d  

^a CNRS   (France)

^b UNIVERSITÉ DE NANTES   (France)

^c UMR 7359   (France)

^d NANTES UNIVERSITY HOSPITAL   (France)

Author keywords

Bendamustine; Cell cycle and apoptosis changes; Drug resistance; Melphalan; Myeloma; P53

Indexed keywords

BENDAMUSTINE; MELPHALAN; PROTEIN P53; REACTIVE OXYGEN METABOLITE; CHLORMETHINE DERIVATIVE;

ARTICLE; CELL DEATH; DRUG MECHANISM; HUMAN; HUMAN CELL; LD 50; MYELOMA CELL; PRIORITY JOURNAL; DRUG EFFECTS; DRUG POTENTIATION; DRUG RESISTANCE; GENETICS; METABOLISM; MULTIPLE MYELOMA; SIGNAL TRANSDUCTION; TUMOR CELL LINE;

CELL DEATH; CELL LINE, TUMOR; DRUG RESISTANCE, NEOPLASM; DRUG SYNERGISM; HUMANS; MELPHALAN; MULTIPLE MYELOMA; NITROGEN MUSTARD COMPOUNDS; REACTIVE OXYGEN SPECIES; SIGNAL TRANSDUCTION; TUMOR SUPPRESSOR PROTEIN P53;

EID: 84906070157     PISSN: 10428194     EISSN: 10292403     Source Type: Journal    
DOI: 10.3109/10428194.2013.871277     Document Type: Article

References (35)

1. Cheson BD, Rummel MJ. Bendamustine: rebirth of an old drug. J Clin Oncol 2009; 27: 1492-1501.
2. Berenson JR, Yellin O, Bessudo A, et al. Phase I/II trial assessing bendamustine plus bortezomib combination therapy for the treatment of patients with relapsed or refractory multiple myeloma. Br J Haematol 2013; 160: 321-330.
3. Lentzsch S, O'Sullivan A, Kennedy RC, et al. Combination of bendamustine, lenalidomide, and dexamethasone (BLD) in patients with relapsed or refractory multiple myeloma is feasible and highly effective: results of phase 1/2 open-label, dose escalation study. Blood 2012; 119: 4608-4613.
4. Michael M, Bruns I, Bolke E, et al. Bendamustine in patients with relapsed or refractory multiple myeloma. Eur J Med Res 2010; 15: 13-19.
5. Ramasamy K, Hazel B, Mahmood S, et al. Bendamustine in combination with thalidomide and dexamethasone is an effective therapy for myeloma patients with end stage renal disease. Br J Haematol 2011; 155: 632-634.
6. Ponisch W, Andrea M, Wagner I, et al. Successful treatment of patients with newly diagnosed/untreated multiple myeloma and advanced renal failure using bortezomib in combination with bendamustine and prednisone. J Cancer Res Clin Oncol 2012; 138: 1405-1412.
7. Rothbarth J, Vahrmeijer AL, Mulder GJ. Modulation of cytostatic efficacy of melphalan by glutathione: mechanisms and efficacy. Chem Biol Interact 2002; 140: 93-107.
8. Kyle RA, Rajkumar SV. Treatment of multiple myeloma: a comprehensive review. Clin Lymphoma Myeloma 2009; 9: 278-288.
9. S trumberg D, H arstrick A, D oll K, et al. Bendamustine hydrochloride activity against doxorubicin-resistant human breast carcinoma cell lines. Anticancer Drugs 1996; 7: 415-421.
10. Leoni LM, Bailey B, Reifert J, et al. Bendamustine (Treanda) displays a distinct pattern of cytotoxicity and unique mechanistic features compared with other alkylating agents. Clin Cancer Res 2008; 14: 309-317.
11. Beeharry N, Rattner JB, Bellacosa A, et al. Dose dependent effects on cell cycle checkpoints and DNA repair by bendamustine. PLoS One 2012; 7: e40342.
12. Chen Q, Van der Sluis P C, Boulware D, et al. The FA/BRCA pathway is involved in melphalan-induced DNA interstrand cross-link repair and accounts for melphalan resistance in multiple myeloma cells. Blood 2005; 106: 698-705.
13. Biroccio A, Benassi B, Fiorentino F, et al. Glutathione depletion induced by c-Myc downregulation triggers apoptosis on treatment with alkylating agents. Neoplasia 2004; 6: 195-206.
14. Cives M, Ciavarella S, Rizzo FM, et al. Bendamustine overcomes resistance to melphalan in myeloma cell lines by inducing cell death through mitotic catastrophe. Cell Signal 2013; 25: 1108-1117.
15. Moreaux J, Klein B, Bataille R, et al. A high-risk signature for patients with multiple myeloma established from the molecular classification of human myeloma cell lines. Haematologica 2011; 96: 574-582.
16. Surget S, Chiron D, Gomez-Bougie P, et al. Cell death via DR5, but not DR4, is regulated by p53 in myeloma cells. Cancer Res 2012; 72: 4562-4573.
17. Bergamo A, Bataille R, Pellat-Deceunynck C. CD40 and CD95 induce programmed cell death in the human myeloma cell line XG2. Br J Haematol 1997; 97: 652-655.
18. Avet-Loiseau H, Attal M, Campion L, et al. Long-term analysis of the IFM 99 trials for myeloma: cytogenetic abnormalities [t(4;14), del(17p), 1q gains] play a major role in defining long-term survival. J Clin Oncol 2012; 30: 1949-1952.
19. Avet-Loiseau H, Durie BG, Cavo M, et al. Combining fluorescent in situ hybridization data with ISS staging improves risk assessment in myeloma: an International Myeloma Working Group collaborative project. Leukemia 2013; 27: 711-717.
20. Moreau P, Avet-Loiseau H, Harousseau JL, et al. Current trends in autologous stem-cell transplantation for myeloma in the era of novel therapies. J Clin Oncol 2011; 29: 1898-1906.
21. Avet-Loiseau H, Leleu X, Roussel M, et al. Bortezomib plus dexamethasone induction improves outcome of patients with t(4;14) myeloma but not outcome of patients with del(17p). J Clin Oncol 2010; 28: 4630-4634.
22. McHugh PJ, Spanswick V J, Hartley J A. Repair of DNA interstrand crosslinks: molecular mechanisms and clinical relevance. Lancet Oncol 2001; 2: 483-490
23. Nojima K, Hochegger H, S aberi A, et al. Multiple repair pathways mediate tolerance to chemotherapeutic cross-linking agents in vertebrate cells. Cancer Res 2005; 65: 11704-11711.
24. Spanswick VJ, Craddock C, Sekhar M, et al. Repair of DNA interstrand crosslinks as a mechanism of clinical resistance to melphalan in multiple myeloma. Blood 2002; 100: 224-229.
25. Kassambara A, Klein B, Moreaux J. MMSET is overexpressed in cancers: link with tumor aggressiveness. Biochem Biophys Res Commun 2009; 379: 840-845.
26. Pei H, Wu X, Liu T, et al. The histone methyltransferase MMSET regulates class switch recombination. J Immunol 2013; 190: 756-763.
27. Pei H, Zhang L, Luo K, et al. MMSET regulates histone H4K20 methylation and 53BP1 accumulation at DNA damage sites. Nature 2011; 470: 124-128.
28. Landau HJ, McNeely SC, Nair JS, et al. The checkpoint kinase inhibitor AZD7762 potentiates chemotherapy-induced apoptosis of p53-mutated multiple myeloma cells. Mol Cancer Ther 2012; 11: 1781-1788.
29. Muldoon LL, Walker-Rosenfeld SL, Hale C, et al. Rescue from enhanced alkylator-induced cell death with low molecular weight sulfur-containing chemoprotectants. J Pharmacol Exp Ther 2001; 296: 797-805.
30. Gomez-Bougie P, Oliver L, Le Gouill S, et al. Melphalan-induced apoptosis in multiple myeloma cells is associated with a cleavage of Mcl-1 and Bim and a decrease in the Mcl-1/Bim complex. Oncogene 2005; 24: 8076-8079.
31. Montero J, Dutta C, van Bodegom D, et al. p53 regulates a non-apoptotic death induced by ROS. Cell Death Differ 2013; 20: 1465-1474.
32. Lee CK, Wang S, Huang X, et al. HDAC inhibition synergistically enhances alkylator-induced DNA damage responses and apoptosis in multiple myeloma cells. Cancer Lett 2010; 296: 233-240.
33. Morandell S, Yaffe MB. Exploiting synthetic lethal interactions between DNA damage signaling, checkpoint control, and p53 for targeted cancer therapy. Prog Mol Biol Transl Sci 2012; 110: 289-314.
34. Damaj G, Malard F, Hulin C, et al. Efficacy of bendamustine in relapsed/refractory myeloma patients: results from the French compassionate use program. Leuk Lymphoma 2012; 53: 632-634.
35. M ark T M, R eid W, N iesvizky R, et al. A phase 1 study of bendamustine and melphalan conditioning for autologous stem cell transplantation in multiple myeloma. Biol Blood Marrow Transplant 2013; 19: 831-837.